SN-38, the active metabolite of irinotecan, inhibits the acute inflammatory response by targeting toll-like receptor 4

ConclusionsTherefore, SN-38 inhibits acute inflammation by blocking LPS-driven TLR4 signaling. This mechanism seems to be shared by other Top I inhibitors.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research